Collegium Pharmaceutical, Inc. (COLL) financial statements (2020 and earlier)

Company profile

Business Address 100 TECHNOLOGY CENTER DRIVE
STOUGHTON, MA 02072
State of Incorp. VA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17014711915396
Cash and cash equivalents17014711915396
Receivables7378102 
Inventory, net of allowances, customer advances and progress billings10821 
Inventory10821 
Prepaid expense13111
Deferred costs    0
Other current assets01000
Other undisclosed current assets2111 
Total current assets:25623813315997
Noncurrent Assets
Operating lease, right-of-use asset9
Property, plant and equipment129211
Intangible assets, net (including goodwill), including:3044 2 
Other undisclosed intangible assets, net (including goodwill)3044 2 
Restricted cash and investments  000
Other noncurrent assets0000 
Total noncurrent assets:5154231
TOTAL ASSETS:30629113616298
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities404314186
Accounts payable612694
Accrued liabilities3331992
Debt42 33
Other undisclosed current liabilities158145175 
Total current liabilities:20218931268
Noncurrent Liabilities
Long-term debt and lease obligation1710 14
Long-term debt, excluding current maturities810 14
Operating lease, liability9
Liabilities, other than long-term debt 1 00
Deferred revenue and credits 00
Other liabilities 1   
Total noncurrent liabilities:1711 24
Total liabilities:219200312713
Stockholders' equity
Stockholders' equity attributable to parent, including:879210413585
Common stock00000
Additional paid in capital447429402358214
Accumulated deficit(360)(337)(298)(223)(129)
Other undisclosed stockholders' equity attributable to parent    (0)
Total stockholders' equity:879210413585
TOTAL LIABILITIES AND EQUITY:30629113616298

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues297280282 
Revenue, net282 
Cost of revenue
(Cost of Goods and Services Sold)
(194)(166)(3)(0) 
Gross profit:103115261 
Operating expenses(127)(135)(101)(96)(27)
Other undisclosed operating income   0 
Operating loss:(24)(21)(75)(94)(27)
Nonoperating income (expense)221(0)(0)
Investment income, nonoperating22   
Other nonoperating income (expense)  1(0)(0)
Interest and debt expense(1)(20) (0)0
Net loss:(23)(39)(75)(94)(27)
Other undisclosed net income (loss) attributable to parent   0(0)
Net loss available to common stockholders, diluted:(23)(39)(75)(94)(27)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(23)(39)(75)(94)(27)
Comprehensive loss, net of tax, attributable to parent:(23)(39)(75)(94)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: